Microbiota-Modulating Strategies in Neonates Undergoing Surgery for Congenital Gastrointestinal Conditions: A...

Area of Science:

• Pediatric Surgery
• Microbiome Research
• Neonatal Care

Background:

• The gut microbiota (GM) is crucial for infant health, influencing immunity, metabolism, and neurodevelopment.
• Infants with congenital gastrointestinal anomalies undergoing surgery often experience gut dysbiosis, marked by reduced beneficial bacteria and impaired short-chain fatty acid production.
• This dysbiosis is linked to severe complications like necrotizing enterocolitis, sepsis, and feeding intolerance.

Purpose of the Study:

• To critically review strategies for modulating the gut microbiota in neonates with congenital gastrointestinal surgical conditions.
• To compare the gut microbiota evolution in healthy neonates versus those requiring gastrointestinal surgery.
• To evaluate emerging techniques for analyzing microbial dynamics in this patient population.

Main Methods:

• Conducted an extensive literature analysis on gut microbiota evolution and modulation strategies.
• Synthesized data on nutritional interventions (human milk), antibiotic management, and supplementary treatments (probiotics, prebiotics, postbiotics, lactoferrin).
• Evaluated metagenomic and metabolomic analysis techniques for elucidating microbial dynamics.

Main Results:

• Neonates undergoing gastrointestinal surgery show significant gut microbial alterations, with decreased beneficial bacteria and increased opportunistic pathogens.
• Early enteral feeding with human milk and judicious antibiotic use correlate with improved microbial balance.
• Adjunctive therapies like probiotics and lactoferrin demonstrate potential for enhancing gut barrier function and immune modulation, pending larger studies.

Conclusions:

• Gut microbiota modulation is a promising strategy to improve outcomes for neonates with congenital gastrointestinal surgical conditions.
• Standardized therapeutic protocols and rigorous multicenter trials are needed to validate the efficacy and safety of these interventions.
• Further research is essential to optimize the management of gut dysbiosis in this vulnerable population.